secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2026-10-01T11:45:14+00:00
Accession:  0001683168-26-007514
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Valion Bio completes oral mucosal Entolimod formulation work with Shear Kershman Laboratories
--------------------------------------------------------------------------------

- Valion Bio and Shear Kershman Laboratories completed formulation work for an oral mucosal Entolimod using SKL's BioViscid drug-delivery platform.
- The program is a potential second, needle-free pathway alongside Valion's injectable Entolimod; next study will test measurable systemic exposure to Entolimod.
- Valion estimates U.S. doses for oral mucosal Entolimod could be 10 to 40 times its injectable program, assuming supply to ~2.0M military, 1.0M firefighters and 790,000 law enforcement officers.
- Valion holds an exclusive worldwide license from Statera Biopharma to develop and commercialize Entolimod for acute radiation syndrome and radiation-induced neutropenia.
- The release says all FDA-approved products address only hematopoietic ARS, and no treatment is approved for the gastrointestinal indication.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826007514/0001683168-26-007514-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826007514/valion_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-007514

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer